Medline Inc.
MDLN
Analytical Summary
Medline Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.
5-Year Financial Trajectory
QuarterlyBullish Indicators
- No bullish signals detected.
Bearish Risks
- Debt to EquityDebt to Equity is concerning (bottom quartile)
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q1 FY2026 Mar 28, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 29, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Revenue Growth YoY (%) |
10.7%
Good
Good
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+33%)
|
— | — | — | — |
| Net Income Growth YoY (%) |
-25.1%
Weak
Weak
Year-over-year change in net income |
— | — | — | — |
| Metric | Q1 FY2026 Mar 28, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 29, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Operating Margin (%) (%) |
5.7%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-62%)
|
— |
8.6%
Caution
Caution
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-43%)
|
— | — |
| Effective Tax Rate (%) (%) |
17.9%
Good
Good
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
4.7%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — |
| Profit Margin (%) (%) |
3.3%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-73%)
|
— |
4.8%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-60%)
|
— | — |
| FCF Margin (%) (%) |
4.3%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— |
8.8%
Caution
Caution
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— | — |
| FCF / Net Income (x) |
1.32x
Good
Good
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
1.83x
Excellent
Excellent
Free cash flow relative to reported net income
Optimal:
> 1x
|
— | — |
| Metric | Q1 FY2026 Mar 28, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 29, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Return on Invested Capital (%) |
1.5%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — | — | — |
| Return on Capital (%) (%) |
1.1%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — | — |
| Return on Common Equity (%) (%) |
2.1%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-86%)
|
— | — | — | — |
| Metric | Q1 FY2026 Mar 28, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 29, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Debt to Equity (x) |
1.11x
Caution
Caution
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Above avg (+85%)
|
1.16x
Caution
Caution
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Above avg (+94%)
|
— | — | — |
| Interest Coverage (x) |
6.92x
Good
Good
Operating income divided by interest expense
Optimal:
> 5x
|
— |
4.20x
Fair
Fair
Operating income divided by interest expense
Optimal:
> 5x
|
— | — |
| Net Debt (USD) | $10.26B | $10.55B | — | $16.22B | — |
| Debt / EBITDA (x) |
18.49x
Weak
Weak
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— | — | — | — |
| Metric | Q1 FY2026 Mar 28, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 29, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $7.35B | — | $6.64B | — | — |
| Depreciation Expense (USD) | $254.00M | — | $247.00M | — | — |
| Net Income, GAAP (USD) | $239.00M | — | $319.00M | — | — |
| Operating Cash Flow (USD) | $412.00M | — | $682.00M | — | — |
Secondary lens
Benchmark Lens
Compare MDLN against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare MDLN against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for MDLN
No bullish signals detected
Debt to Equity is concerning (bottom quartile)
Percentile Rankings
How MDLN compares to all companies
Peer Comparison
MDLN vs similar peers
Compare MDLN with peers
Stack MDLN against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 3 years · 5 quarters